BPC-157 + TB-500 Stack Protocol Guide
The BPC-157 + TB-500 combo stack is the most popular recovery peptide blend in research, combining two complementary healing peptides in a single vial. BPC-157 (Body Protection Compound) excels at localized tissue repair through angiogenesis and growth factor upregulation, while TB-500 (Thymosin Beta-4 fragment) provides systemic anti-inflammatory effects and promotes cellular migration to injury sites. Together they create synergistic healing that addresses both local tissue damage and systemic recovery. This protocol covers reconstitution from a 20mg total blend vial (10mg BPC-157 + 10mg TB-500), subcutaneous dosing at 250mcg daily, and advanced stacking for accelerated recovery.
Protocol Overview
- Compound
- BPC-157 + TB-500 (Recovery Blend)
- Category
- Tissue Repair / Recovery Stack
- Mechanism
- BPC-157: angiogenesis, VEGF/EGF upregulation, nitric oxide modulation. TB-500: actin sequestration, cellular migration, systemic anti-inflammatory, stem cell differentiation
- Blend Ratio
- 1:1 (10mg BPC-157 + 10mg TB-500)
- Half-Life
- BPC-157: ~4hrs | TB-500: ~6-8hrs
- Vial Size
- 20mg total lyophilized blend
- Route
- Subcutaneous injection
- Frequency
- Once daily (AM)
- Cycle Length
- 4-8 weeks
Dosing Protocol
| Protocol | Dose (Blend) | Frequency | Route | Duration |
|---|---|---|---|---|
| Standard Recovery | 250 mcg | 1x daily (AM) | Subcutaneous near injury | 4-6 weeks |
| Aggressive Healing | 500 mcg | 1x daily (AM) | Subcutaneous near injury | 4-8 weeks |
| Maintenance | 250 mcg | Every other day | Subcutaneous | 2-4 weeks |
- 250 mcg blend = 125 mcg BPC-157 + 125 mcg TB-500 (low end; BPC-157 is adequate, TB-500 is sub-therapeutic)
- 500 mcg blend = 250 mcg BPC-157 + 250 mcg TB-500 (standard BPC-157 dose; TB-500 still below typical 2mg target)
- 2 mg blend = 1 mg BPC-157 + 1 mg TB-500 (higher dose approach; recommended when TB-500 activity is the primary goal)
- 4 mg blend = 2 mg BPC-157 + 2 mg TB-500 (full therapeutic TB-500 dose; monitor BPC-157 at this level)
Note: If maximizing TB-500 activity (e.g., systemic anti-inflammatory, fibrosis reduction), consider dosing 2–4 mg of this blend per injection. For localized BPC-157 healing focus only, 250–500 mcg is sufficient.
Key principle: Inject as close to the injury site as possible for localized healing. For systemic recovery benefits, subcutaneous abdominal injection is appropriate.
Reconstitution Instructions
Materials Needed
- BPC-157 + TB-500 blend vial (10mg + 10mg)
- Bacteriostatic water (2mL)
- 3mL mixing syringe (18-20ga)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol
- Draw 2mL bacteriostatic water
- Inject slowly down the vial wall
- Gently swirl (never shake)
- Wait 5 minutes for full dissolution
- Concentration: 10,000 mcg/mL
| Dose | Volume (2mL recon) | Insulin Syringe |
|---|---|---|
| 250 mcg | 0.025 mL | 2.5 units |
| 500 mcg | 0.05 mL | 5 units |
| 1,000 mcg | 0.10 mL | 10 units |
| 2,000 mcg | 0.20 mL | 20 units |
Administration Guide
Injection Sites
- Near injury: Subcutaneous as close to injury as possible
- Shoulder: Over deltoid/rotator cuff area
- Knee: Medial or lateral knee
- Systemic: Abdomen, 2 inches from navel
Timing & Storage
- Timing: Morning on an empty stomach
- Vial duration: ~80 days at 250mcg/day
- Storage: Refrigerate 2-8°C, use within 30 days
- Do not freeze reconstituted solution
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site redness or irritation (mild, transient)
- Mild dizziness (uncommon)
- Warmth or flushing at injection site
- Mild lethargy during first few days
Both BPC-157 and TB-500 have excellent safety profiles in research literature with no significant adverse effects at standard doses.
Precautions
- May theoretically promote angiogenesis in existing tumors
- Avoid if active cancer or cancer history (precautionary)
- Limited human clinical trial data
- Not recommended during pregnancy or breastfeeding
Stacking Recommendations
Compatible Compounds
- GHK-Cu: Tissue remodeling and collagen support
- Ipamorelin: GH release for recovery enhancement
- Glutathione: Antioxidant support during healing
- Collagen peptides: Building blocks for repair
- NAD+: Cellular energy for tissue regeneration
Popular Stacks
- Ultimate Healing: BPC-157/TB-500 blend + GHK-Cu + Ipamorelin
- Joint Recovery: BPC-157/TB-500 + Collagen + Glutathione
- Athletic Recovery: BPC-157/TB-500 + CJC-1295/Ipamorelin
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Inflammatory | CRP, ESR, IL-6 | Baseline, Week 4 |
| Basic Panel | CBC, CMP | Baseline, Week 4 |
| Liver Function | ALT, AST | Baseline, Week 4 |
Blood work is primarily to track healing-related inflammatory markers. CRP and ESR should trend downward as healing progresses.
Related Tools & Resources
BPC-157 and TB-500 work through complementary mechanisms. BPC-157 excels at localized healing through angiogenesis and growth factor upregulation, while TB-500 provides systemic anti-inflammatory effects and promotes cellular migration to injury sites. Together they create a synergistic healing response that addresses both local tissue repair and systemic recovery.
Add 2mL of bacteriostatic water to the 20mg total blend vial for a concentration of 10mg/mL (10,000mcg/mL). Each 2.5 units on an insulin syringe delivers 250mcg of the blend. Reconstituted solution should be refrigerated and used within 30 days.
There is no validated human dose for this compound; the following is a commonly cited research convention, not a validated protocol. The standard BPC-157 + TB-500 blend protocol uses 250mcg of the combined blend administered subcutaneously once daily in the morning, 5 days per week. The pre-blended vial contains equal parts BPC-157 and TB-500 (10mg each, 20mg total), reconstituted with 2mL bacteriostatic water for a concentration of 10mg/mL.
BPC-157 and TB-500 work through complementary mechanisms. BPC-157 excels at localized healing through angiogenesis and growth factor upregulation, while TB-500 provides systemic anti-inflammatory effects and promotes cellular migration to injury sites. Together they create a synergistic healing response that addresses both local tissue repair and systemic recovery.
Add 2mL of bacteriostatic water to the 20mg total blend vial for a concentration of 10mg/mL (10,000mcg/mL). Each 2.5 units on an insulin syringe delivers 250mcg of the blend. Reconstituted solution should be refrigerated and used within 30 days.